X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (105) 105
middle aged (94) 94
oncology (92) 92
female (90) 90
male (89) 89
aged (80) 80
adult (67) 67
index medicus (65) 65
chemotherapy (53) 53
lung neoplasms - pathology (49) 49
lung neoplasms - drug therapy (45) 45
cancer (35) 35
treatment outcome (35) 35
antineoplastic combined chemotherapy protocols - therapeutic use (33) 33
lung cancer (33) 33
respiratory system (33) 33
aged, 80 and over (32) 32
carcinoma, non-small-cell lung - drug therapy (30) 30
cisplatin (27) 27
retrospective studies (26) 26
non-small cell lung cancer (25) 25
cisplatin - administration & dosage (23) 23
adenocarcinoma (21) 21
carcinoma, non-small-cell lung - pathology (21) 21
prognosis (21) 21
pulmonary/respiratory (21) 21
docetaxel (20) 20
hematology, oncology and palliative medicine (20) 20
lung neoplasms - mortality (20) 20
neoplasm staging (19) 19
lung cancer, non-small cell (18) 18
care and treatment (17) 17
mutation (17) 17
trial (17) 17
disease-free survival (15) 15
survival analysis (15) 15
tumors (15) 15
antineoplastic agents - therapeutic use (14) 14
carcinoma (14) 14
lung neoplasms - genetics (14) 14
analysis (13) 13
expression (13) 13
survival rate (13) 13
carboplatin (12) 12
gefitinib (12) 12
lung cancer, small cell (12) 12
metastasis (12) 12
small cell lung cancer (12) 12
survival (12) 12
vinorelbine (12) 12
young adult (12) 12
adolescent (11) 11
carcinoma, non-small-cell lung - mortality (11) 11
lung neoplasms - therapy (11) 11
research (11) 11
adenocarcinoma - pathology (10) 10
antineoplastic agents - adverse effects (10) 10
antineoplastic combined chemotherapy protocols - adverse effects (10) 10
cancer research (10) 10
cisplatin - adverse effects (10) 10
immunohistochemistry (10) 10
small cell lung carcinoma - drug therapy (10) 10
therapy (10) 10
drug administration schedule (9) 9
hematology (9) 9
infusions, intravenous (9) 9
medicine & public health (9) 9
paclitaxel (9) 9
pathology (9) 9
amrubicin (8) 8
cell lung-cancer (8) 8
cells (8) 8
chemoradiotherapy (8) 8
follow-up studies (8) 8
immunophenotyping (8) 8
medical research (8) 8
multicenter (8) 8
oncology, experimental (8) 8
quinazolines - therapeutic use (8) 8
small cell lung carcinoma - pathology (8) 8
toxicity (8) 8
1st-line treatment (7) 7
adjuvant chemotherapy (7) 7
antimitotic agents (7) 7
antineoplastic agents (7) 7
breast-cancer (7) 7
dose-response relationship, drug (7) 7
gemcitabine (7) 7
genetic aspects (7) 7
japan (7) 7
kaplan-meier estimate (7) 7
open-label (7) 7
paclitaxel - administration & dosage (7) 7
phase-ii trial (7) 7
polymerase chain reaction (7) 7
receptor, epidermal growth factor - genetics (7) 7
adenocarcinoma of lung (6) 6
antineoplastic agents - administration & dosage (6) 6
biopsy (6) 6
carcinoma, non-small-cell lung - genetics (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Oncology, ISSN 0923-7534, 10/2014, Volume 25, Issue suppl_5, pp. v28 - v28
Journal Article
The Lancet Oncology, ISSN 1470-2045, 11/2017, Volume 18, Issue 11, pp. 1454 - 1466
Journal Article
Japanese Journal of Lung Cancer, ISSN 0386-9628, 10/2015, Volume 55, Issue 6, pp. 932 - 935
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 02/2017, Volume 23, Issue 3, pp. 757 - 765
Purpose: Although large-cell neuroendocrine carcinoma (LCNEC) of the lung shares many clinical characteristics with small-cell lung cancer (SCLC), little is... 
GENE | CISPLATIN | ONCOLOGY | PATHWAY | IMATINIB | MULTICENTER-PHASE-II | DNA-SEQUENCING DATA | CANCER | EXPRESSION | CHEMOTHERAPY | C-KIT PROTEIN | Carcinoma, Small Cell - surgery | Predictive Value of Tests | Adenocarcinoma - pathology | Carcinoma, Small Cell - genetics | Follow-Up Studies | Carcinoma, Large Cell - pathology | Genes, Neoplasm | Humans | Middle Aged | Male | Gene Expression Profiling | Young Adult | Sensitivity and Specificity | Aged, 80 and over | Adult | Female | Adenocarcinoma - genetics | Carcinoma, Large Cell - genetics | Neoplasm Proteins - genetics | Carcinoma, Non-Small-Cell Lung - pathology | Carcinoma, Non-Small-Cell Lung - surgery | Carcinoma, Non-Small-Cell Lung - genetics | Neoplasm Proteins - biosynthesis | Carcinoma, Neuroendocrine - genetics | Carcinoma, Neuroendocrine - surgery | Exons - genetics | Gene Dosage | Biopsy | Carcinoma, Large Cell - surgery | Carcinoma, Neuroendocrine - pathology | Aged | Mutation | Carcinoma, Small Cell - pathology | Adenocarcinoma - surgery | TOR protein | Profiling | Small cell lung carcinoma | Epidermal growth factor receptors | Exons | p53 Protein | Lung cancer | AKT2 protein | Non-small cell lung carcinoma | AKT protein | Lung carcinoma | ErbB-2 protein | K-Ras protein | 1-Phosphatidylinositol 3-kinase | Gene sequencing | Alterations | Experimental design | Coding | Fibroblast growth factor receptor 1 | PTEN protein | Tumors | Cancer
Journal Article
Cancer Science, ISSN 1347-9032, 01/2017, Volume 108, Issue 1, pp. 136 - 142
Metastasis and growth in neoplastic lesions requires the multistep regulation of microenvironmental factors. We aimed to elucidate the microenvironmental... 
micrometastasis | macrometastasis | Cancer microenvironment | lung squamous cell carcinoma | lymph node metastasis | CHEMOTHERAPY PLUS CETUXIMAB | ANOIKIS | ADENOCARCINOMA | MICROMETASTASES | BREAST-CANCER | ONCOLOGY | EGFR EXPRESSION | FLEX | RECURRENCE | Lung Neoplasms - genetics | Microvessels - cytology | Geminin - metabolism | ErbB Receptors - metabolism | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - pathology | Humans | Stromal Cells - metabolism | Gene Expression Regulation, Neoplastic | Microvessels - metabolism | Transcriptome | Lung Neoplasms - pathology | Macrophages - cytology | Disease Progression | Necrosis | Myofibroblasts - cytology | Myofibroblasts - metabolism | Mitotic Index | Macrophages - metabolism | Tumor Microenvironment - genetics | Neoplastic Stem Cells - metabolism | Epithelial-Mesenchymal Transition | Lymphatic Metastasis - genetics | Stromal Cells - cytology | Fibroblast growth factor | Lung cancer | S100A4 protein | Smooth muscle | Metastasis | Macrophages | Aldehyde dehydrogenase | Lymph nodes | Metastases | Ethics | Epidermal growth factor | Actin | CD44 antigen | Fibroblasts | Geminin | Fibroblast growth factor receptor 2 | CD34 antigen | Lymphatic system | Squamous cell carcinoma | Immunoglobulins | Review boards | Research & development--R&D | Tumor cells | Ezrin | Lung carcinoma | Gene expression | Endothelium | Studies | Stromal cells | Medical prognosis | Morphology | Minimum inhibitory concentration | Tumors | Original
Journal Article
Cancer Science, ISSN 1347-9032, 03/2016, Volume 107, Issue 3, pp. 315 - 319
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2016, Volume 27, Issue suppl_7
Journal Article
Cancer Research, ISSN 0008-5472, 05/2018, Volume 78, Issue 9, pp. 2179 - 2190
Journal Article
Nature Communications, ISSN 2041-1723, 12/2018, Volume 9, Issue 1, pp. 625 - 9
Resistance to vandetanib, a type I RET kinase inhibitor, developed in a patient with metastatic lung adenocarcinoma harboring a CCDC6-RET fusion that initially... 
CELL LUNG-CANCER | MOLECULAR-DYNAMICS | PRECISION MEDICINE | FUSION | MODEL | MULTIDISCIPLINARY SCIENCES | Adenocarcinoma | Phenylalanine | Serine | Activation | Hydrophobicity | Drug resistance | Kinases | Metastases | Allosteric properties | Missense mutation | Lungs | Mutation | Crystal structure
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2018, Volume 36, Issue 22, pp. 2244 - 2250
PurposeARCHER 1050, a randomized, open-label, phase III study of dacomitinib versus gefitinib in treatment-naive patients with advanced non-small-cell lung... 
1ST-LINE TREATMENT | CONTROLLED-TRIAL | MULTICENTER | ONCOLOGY | ADENOCARCINOMA | PHASE-3 TRIAL | OPEN-LABEL | AFATINIB | INHIBITOR | CHEMOTHERAPY | ERLOTINIB
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2017, Volume 28, Issue suppl_9
Journal Article
Journal Article
Journal Article